Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Accumulated Depreciation: 2015-2022

  • Spyre Therapeutics' Accumulated Depreciation rose 47.89% to $4.1 million in Q4 2022 from the same period last year, while for Dec 2022 it was $4.1 million, marking a year-over-year increase of 47.89%. This contributed to the annual value of $4.1 million for FY2022, which is 47.89% up from last year.
  • As of Q4 2022, Spyre Therapeutics' Accumulated Depreciation stood at $4.1 million, which was up 47.89% from $2.8 million recorded in Q4 2021.
  • In the past 5 years, Spyre Therapeutics' Accumulated Depreciation registered a high of $4.1 million during Q4 2022, and its lowest value of $752,000 during Q4 2018.
  • Moreover, its 3-year median value for Accumulated Depreciation was $2.8 million (2021), whereas its average is $3.0 million.
  • Data for Spyre Therapeutics' Accumulated Depreciation shows a peak YoY skyrocketed of 87.96% (in 2020) over the last 5 years.
  • Over the past 5 years, Spyre Therapeutics' Accumulated Depreciation (Quarterly) stood at $752,000 in 2018, then soared by 40.29% to $1.1 million in 2019, then surged by 87.96% to $2.0 million in 2020, then spiked by 41.30% to $2.8 million in 2021, then skyrocketed by 47.89% to $4.1 million in 2022.
  • Its Accumulated Depreciation was $4.1 million in Q4 2022, compared to $2.8 million in Q4 2021 and $2.0 million in Q4 2020.